|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers显示文摘BACKGROUND Gemcitabine plus platinum is the standard of care first-line treatment for advanced biliary tract cancers(BTC).There is no established second-line therapy,and retrospective reviews report median progression-free survival(PFS)less than 3 mo on second-line therapy.5-Fluorouracil plus irinotecan(FOLFIRI)is a commonly used regimen in patients with BTC who have progressed on gemcitabine plus platinum,though there is a paucity of data regarding its efficacy in this population.AIM To assess the efficacy of FOLFIRI in patients with biliary tract cancers.METHODS We retrospectively identified patients with advanced BTC who were treated with FOLFIRI at MD Anderson,University of Michigan and Mayo Clinic in Jacksonville.Data were collected on patient demographics,BTC subtype,response per RECIST v1.1,progression and survival.RESULTS Ninety-eight patients were included of which 74(75%)had metastatic and 24(25%)had locally advanced disease at the time of treatment with FOLFIRI.The median age was 60(range,22-86)years.The number of patients with extrahepatic cholangiocarcinoma,gall bladder cancer and intrahepatic cholangiocarcinoma were 10,17 and 71,respectively.FOLFIRI was used as 1st,2nd,3rd or 4th–Nth lines in 8,50,36 and 4 patients,respectively.Median duration on FOLFIRI in the entire cohort was 2.2(range,0.5-8.4)mo.The median PFS and overall survival were 2.4(95%confidence interval(CI):1.7-3.1)and 6.6(95%CI:4.7-8.4)mo,respectively.Median PFS for patients treated with FOLFIRI in 1st,2nd,3rd or 4th–Nth lines were 3.1,2.5,2.3 and 1.5 mo,respectively.Eighteen patients received concurrent bevacizumab(n=13)or EGFR-targeted therapy(n=5)with FOLFIRI,with a median PFS of 2.7 mo(95%CI:1.7-5.1).CONCLUSION In this largest multi-institution retrospective review of 98 patients with BTC treated with FOLFIRI,efficacy appears to be modest with outcomes similar to other cytotoxic chemotherapy regimens. | Jonathan D Mizrahi Valerie Gunchick Kabir Mody Lianchun Xiao Phanikeerthi Surapaneni Rachna T Shroff Vaibhav Sahai | 2020 | World Journal of Gastrointestinal Oncology2020，12，1： | 2 |
| 2 | An adaptive approach to controllingKanban systems显示文摘 | VALERIE T LARS M | 2001 | European Journal of Operation Research2001，132，2： | 1 |
| 3 | MicroRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer 显示文摘 | Braconi C Kogure T Valeri N | 2011 | Oncogene2011，30，47： | 1 |
| 4 | Catalytic inhibition of laminar flames by transition metal compounds 显示文摘 | Gregory T Linteris Marc D Rumminger Valeri I Babushok | 2008 | Progress in Energy and Combustion Science2008，，34： | 1 |
| 5 | microRNA-29 canregulate expression of the long non-coding RNA gene MEG3 inhepatocellular cancer显示文摘 | Braconi C Kogure T Valeri N | 2011 | Oncogene2011，30，47： | 1 |
| 6 | microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer显示文摘 | Braconi C Kogure T Valeri N | 2011 | Oncogene2011，30，47： | 1 |
| 7 | Irinotecan as firstline hemotherapy in patients with advanced hepatocellular carcinoma: A multicenter phase II study with dose adjustment according to baseline serum billrubin level 显示文摘 | Valerie B Julien T Mohamed H | 2006 | Eur J Can2006，42，4： | 1 |
| 8 | Is z-disk degradation responsible for postmortem tenderization?显示文摘 | RICHARD G T GREET H G VALERY F T | 1995 | J Anim Sci1995，73，： | 1 |
| 9 | microRNA-29 can regulateexpression of the long non-coding RNA gene MEG3 inhepatocellular cancer显示文摘 | Braconi C Kogure T Valeri N | 2011 | Oncogene2011，30，47： | 1 |
| 10 | Syntheses of carbon encapsulated magnetic FeNi nanoparticle via decompositions of methane and benzene显示文摘 | Ioarmis P Valerie C Shik C T | 2006 | Carbon2006，44，4： | 1 |
| 11 | Processing of low -density silica gel by criticai point drying or ambient drying 显示文摘 | Valerie D L Thomas M H Dale C T | 2001 | Non - Cryst Solids2001，283，123： | 1 |
| 12 | Bactericidal and antifungal activities of a low molecu- lar weight chitosan and its N-2 (3)-(dedec-2-enyl) succinoyl / derivatives显示文摘 | Vlandimir E T Evgeniya A S Valery G B | 2006 | Carbohydrate Polymers2006，，64： | 1 |
| 13 | Genome sequence of enterohaemorrhagic Escherichia coli O157:H7显示文摘 | Nicole T Perna Guy Plunkett Valerie Burland | 2001 | Nature2001，409，25： | 1 |
| 14 | Dichloro-diphenytrichloroethane (DDT) : ubiquity, persistence, and risks 显示文摘 | VLADIMIR T VALERY R LORENZO T | 2002 | Research Review2002，110，2： | 1 |
| 15 | microRNA-29 can regulate expression of the long non -coding RNA gene MEG3 in hepatocellular cancer 显示文摘 | Braconi C Kogure T Valeri N | 2011 | Oncogene2011，30，47： | 1 |
| 16 | microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer显示文摘 | Braconi C Kogure T Valeri N | 2011 | Oncogene2011，30，47： | 1 |
| 17 | microRNA-29 can regulate expression of the long noncoding RNA gene MEG3 in hepatocellular cancer显示文摘 | BRACONI C KOGURE T VALERI N | 2011 | Oncogene2011，30，47： | 1 |
| 18 | TRAIL receptor signaling and therapeutic option in bone tumors:the trap of the bone microenvironment显示文摘 | Gaelle P Valerie T Stephane T | | 0，，01： | 1 |
| 19 | Mierovave-as- sistcd water extraction of green tea polyphenols 显示文摘 | Ezzohra N Valerie T Hakima E H | 2009 | Phyto- chem Anal2009，20，： | 1 |
| 20 | microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer 显示文摘 | Braconi C Kogure T Valeri N | 2011 | Oncogene2011，30，47： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员